Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
365 articles on this topic
-
Thymosin Alpha 1 Peptide: The Trial Record
Thymalfasin — the drug form of the thymosin alpha 1 peptide — is approved in over 30 countries, and the largest trial ever run on it, in 1,106 sepsis patients, returned a 28-day mortality hazard ratio of 0.97.
-
What are compounded medications?
What are compounded medications? Preparations a licensed pharmacist makes for one named patient — here is how 503A rules, state licensure, and USP standards govern the work.
-
The DSIP Peptide: A 1970s Sleep Mystery
The DSIP peptide was isolated from the blood of sleeping rabbits in 1970s Switzerland, yet no one has ever found its receptor — or the gene that would prove mammals make it.
-
A Telehealth Doctor Must Be Licensed in Your State
A Promise analysis of FSMB, AMA and CCHP data on the rule that governs every visit: a telehealth doctor must be licensed where the patient is — and the compact system built around that rule issued 3,633 licenses in a single month.
-
What Does Kisspeptin Do? The Signal Above GnRH
Kisspeptin sits one rung above GnRH in the reproductive axis, and the ~4-minute half-life routinely quoted for kisspeptin-10 — the form coming soon to Promise — has been measured in people: 3.8 minutes in men, 4.1 in women.
Page 19 of 19 · 365 articles